4/A

PRIMARY DOCUMENT

Company: NYMOX PHARMACEUTICAL CORP
Filed: May 18, 2023
Period of Report: April 25, 2023
Accession Number: 0001729637-23-000003

View Document ↗ View on SEC.gov ↗